Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

nippon

Biosimilar Remicade reaches market in Japan and India

Biosimilar Remicade reaches market in Japan and India

India. In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean biotechnology company Celltrion, which was approved for marketing in July. ... Nippon Kayaku said infliximab is the second

Deal Watch table for September 2013

Deal Watch table for September 2013 50. 5. Shin Nippon Biomedical  / Transcept Pharma. Licence. TO-2070 nasal powder for acute migraine.

First biosimilar mAb gets the nod in EU

First biosimilar mAb gets the nod in EU In Japan the drug will be co-marketed by Celltrion's development partner Nippon Kayaku. .

New formulations of Pralia and Enbrel head list of new drugs in Japan

New formulations of Pralia and Enbrel head list of new drugs in Japan line extension - which like its predecessor will be co-promoted by Nippon Boehringer Ingelheim - is expected to provide better control of high blood pressure over 24 hours.

An eye towards the biobetter in South Korea

An eye towards the biobetter in South Korea Location. Status. Herceptin (trastuzumab). CT-P6. Celltrion. Hospira, Nippon Kayaku. Breast cancer. ... Remsima. Celltrion. Hospira, Nippon Kayaku. RA, AS, CD, PA, PS, &UC.

1 2 3 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics